Bill > S736

This bill aims to promote comprehensive transparency in the pharmaceutical industry. Key provisions include: - Defining new terms like "early notice", "pharmaceutical manufacturing company", "pharmacy benefit manager", "pipeline drugs", and "sponsor" to provide clarity around key industry players and activities. - Expanding the scope of the Health Policy Commission to include oversight of pharmacy benefit managers and pharmaceutical manufacturing companies, including requiring their participation in Commission hearings and analyses. - Requiring pharmaceutical manufacturers to disclose detailed information about drug pricing, such as wholesale acquisition cost increases, research and development costs, and marketing plans for high-cost drugs. - Authorizing the Commission to identify proposed supplemental rebates for certain high-cost drugs and to assess the reasonableness of manufacturers' drug pricing. - Requiring pharmaceutical manufacturers and pharmacy benefit managers to provide early notice and data on new drugs, generic drugs, and biosimilars that may have a significant impact on state healthcare spending. - Enhancing the Attorney General's and the Center for Health Information and Analysis' authority to monitor and analyze pharmaceutical costs and pricing trends. The overall goal is to increase transparency around pharmaceutical industry practices and costs in order to better understand and control rising healthcare expenditures in Massachusetts.

Health and Social Services

https://malegislature.gov/Bills/192/S736